Articles tagged "Rapamycin"

2016 American Transplant Congress
Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population.
C.-C. Kao,¹ J.-S. Liu,² M.-H. Lin,² F.-C. Chang,¹ Y.-C. Lin,¹ H.-H. Chen,¹ T.-W. Chen,¹ C.-C. Hsu,² M.-S. Wu.¹
¹Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; ²Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
Introduction The mTOR inhibitor is an immunosuppressive drug used in kidney transplantation. Whether the mTOR inhibitors is associated with reduced risk of cancer development in…
2015 American Transplant Congress
"What's the Mileage?" Determining the Length of Time in Which Renal Function Returns to Pre-Calcineurin Discontinuation Levels in Patients With Interstitial Fibrosis
A. Diez, J. Von Visger, U. Nori, T. Pesavento, M. Henry, E. Davies, R. Pelletier.
The Ohio State University, Columbus.
Calcineurin Inhibitors (CNI) use may be associated with progressive renal dysfunction. Clinical trials have shown that CNI minimization or discontinuation may aid in improvement in…
2015 American Transplant Congress
Delayed Tacrolimus (TAC) to Rapamycin (RAPA) Conversion in Renal Transplant Recipients With DGF/SGF
A. Haririan,¹ D. Klassen,¹ M. Keshtkar,¹ C. Drachenberg,² T. Dowling,³ E. Ramos,¹ R. Ugarte,¹ C. Cangro,¹ M. Weir.¹
¹Medicine, University of Maryland, Baltimore, MD; ²Pathology, University of Maryland, Baltimore, MD; ³Pharmacy, University of Maryland, Baltimore, MD.
The role of conversion from TAC to RAPA early after kidney transplantation in patients with DGF/SGF in improving graft function and delaying chronic allograft dysfunction…
2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC.
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…
2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.
Department of Transplantology, General, Vascular and Plastic Surgery, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland.
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…
2015 American Transplant Congress
Associations Between Sirolimus Use and Outcomes After Liver Transplant for Hepatocellular Carcinoma
E. Yanik,¹ S. Chinnakotla,² A. Israni,^2,3 J. Snyder,^2,3 S. Gustafson,³ E. Engels.¹
¹Natl. Cancer Inst., Bethesda, MD; ²U. of Minnesota, Minneapolis, MN; ³Sci. Reg. of Transplant Recipients, Minneapolis, MN.
A growing fraction of U.S. liver transplants are being done for the indication of hepatocellular carcinoma (HCC). HCC recurrence after transplant remains a major concern…
2015 American Transplant Congress
Marked Suppression of Posttransplant Alloantibody Production and Primed B cell Function In Vivo by mTOR Inhibition Compared to Calcineurin Inhibition
C. Wright, J. Zimmerer, T. Pham, G. Bumgardner.
Department of Surgery, CTC, The Ohio State University, Columbus, OH.
mTOR inhibitors [mTORi; Rapamycin, (Rapa)] and calcineurin inhibitors [CNi; Tacrolimus (Tac)] are immunosuppressives commonly used to suppress rejection of transplants. Despite widespread use following transplantation…
2015 American Transplant Congress
Ex Vivo Expansion With Rapamycin Enhances the Suppressive Function of Regulatory T Cells (Tregs) Isolated from Pediatric Thymus
E. Dijke,^1,2,3 R. Hoeppli,^3,4 T. Ellis,^1,2 J. Pearcey,^1,2 I. Larsen,^1,2 I. Rebeyka,^1,2 D. Ross,^1,2 M. Levings,^3,4 L. West.^1,2,3
¹University of Alberta, Edmonton, AB, Canada; ²Alberta Transplant Institute, Edmonton, AB, Canada; ³Canadian National Transplant Research Program, Edmonton/Vancouver, AB/BC, Canada; ⁴University of British Columbia, Vancouver, BC, Canada.
INTRODUCTION: Treg-based cellular therapy to suppress graft-directed immunity could reduce the need for life-long immunosuppressive drugs. Challenges include isolation and expansion of pure Tregs to…
2015 American Transplant Congress
CXCR4-SDF1α Blockade Reduces the Severity of Murine Heart Allograft Rejection
X. Wang,¹ J. Fu,¹ B. Wilde,¹ L. Jing,¹ J. Zhu,¹ A. Kribben,¹ O. Witzke,¹ A. Hoerning.^2,3
¹Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ²Department of Pediatrics II, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ³Department of Pediatric and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander University Erlangen, Erlangen, Germany.
Introduction: The interaction of the CXCR4/SDF1α axis plays a critical role in the retention of hematopoietic stem cells in bone marrow. We hypothesized that the…
2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
B. Oh, G. Furtmüller, M. Fryer, G. Raimondi, D. Cooney, W. Lee, G. Brandacher.
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United Kingdom.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…